How the DEA and FDA will regulate psychedelic medicine

In this week’s episode, we chat with Matt Zorn, an attorney at Yetter Coleman with expertise in DEA law, especially regarding psychedelics. Matt is currently challenging the DEA’s decision to schedule 5 new tryptamines, he recently argued Kathryn Tucker’s psilocybin “Right To Try” case against the DEA, and previously co-led Sue Sisley’s DEA case related to cannabis scheduling. Matt also writes the drug policy newsletter On Drugs.

Credits: 

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis & Zack Frank

Find us at businesstrip.fm
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank